Phio Pharmaceuticals Secures New Investor
17 mai 2024 09h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
16 mai 2024 08h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
15 mai 2024 13h00 HE
|
Phio Pharmaceuticals Corp.
-PH-762 is Phio’s lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
09 mai 2024 17h25 HE
|
Phio Pharmaceuticals Corp.
–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 –Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) --...
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
30 avr. 2024 07h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
22 avr. 2024 13h10 HE
|
Phio Pharmaceuticals Corp.
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma ...
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
16 avr. 2024 07h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
National Spotlight Features Phio’s Innovative RNAi Technology Platform
03 avr. 2024 07h30 HE
|
Phio Pharmaceuticals Corp.
—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp....
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
02 avr. 2024 07h30 HE
|
Phio Pharmaceuticals Corp.
– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments,...
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
13 mars 2024 14h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...